CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia

Journal of Molecular and Cellular Cardiology

Volumn 85, Issue , 2015, Pages 249-261

  Lin, Chih Yuan ^a,b   Hsu, Yu Juei ^a   Hsu, Shih Che ^c   Chen, Ying ^c   Lee, Herng Sheng ^d   Lin, Shih Hua ^a   Huang, Shih Ming ^c   Tsai, Chien Sung ^a   Shih, Chun Che ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Akt; Chronic kidney disease; Fibrosis; Left ventricular hypertrophy; Uremic cardiomyopathy

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BIOLOGICAL MARKER; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; COLLAGEN TYPE 1; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; CANNABINOID RECEPTOR ANTAGONIST; COLLAGEN; PROBENECID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART SIZE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; UREMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; COMPLICATION; FIBROSIS; HYPERTROPHY, LEFT VENTRICULAR; MALE; METABOLISM; PRECLINICAL STUDY; RENAL INSUFFICIENCY, CHRONIC; SPRAGUE DAWLEY RAT;

MUS;

ANIMALS; CANNABINOID RECEPTOR ANTAGONISTS; CELL LINE; COLLAGEN; DRUG EVALUATION, PRECLINICAL; FIBROSIS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE, INBRED C57BL; PROBENECID; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RENAL INSUFFICIENCY, CHRONIC; UREMIA;

EID: 84932647247     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.06.010     Document Type: Article

References (58)

1. Briet M., Boutouyrie P., Laurent S., London G.M. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int 2012, 82:388-400.
2. Foley R.N., Collins A.J. End-stage renal disease in the United States: an update from the United Stated Renal Data System. J Am Soc Nephrol 2007, 18:2644-2648.
3. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
4. Smith G.L., Lichtman J.H., Bracken M.B., Shlipak M.G., Phillips C.O., DiCapua P., et al. Renal impairment and outcomes in heart failure: systemic reviews and meta-analysis. J Am Coll Cardiol 2006, 47:1987-1996.
5. Amann K., Tyralla K., Gross M.L., Schwarz U., Tornig J., Haas C.S., et al. Cardiomyocyte loss in experimental renal failure: prevention by ramipril. Kidney Int 2003, 63:1708-1713.
6. Amann K., Kronenberg G., Gehlen F., Wessels S., Orth S., Munter K., et al. Cardiac remodelling in experimental renal failure-an immunohistochemical study. Nephrol Dial Transplant 1998, 13:1958-1966.
7. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international Forum on cardiac remodeling. J Am Coll Cardiol 2000, 35:568-582.
8. Nitta K., Iimuro S., Imai E., Matsuo S., Makino H., Akizawa T., et al. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease. Clin Exp Nephrol 2013, 17:730-742.
9. Amann K., Ritz E., Wiest G., Klaus G., Mall G. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994, 4:1814-1819.
10. Scheid M.P., Woodgett J.R. PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2001, 2:760-768.
11. Scheid M.P., Woodgett J.R. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 2003, 546:108-112.
12. Vanhaesebroeck B., Alessi D.R. The P13K-PDK1 connection: more than just a road to PKB. Biochem J 2000, 346:561-576.
13. Leevers S.J. Growth control: invertebrate insulin surprises!. Curr Biol 2001, 11:R209-R212.
14. Leevers S.J., Weinkove D., MacDougall L.K., Hafen E., Waterfield M.D. The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J 1996, 15:6584-6594.
15. Shioi T., McMullen J.R., Kang P.M., Douglas P.S., Obata T., Franke T.F., et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 2002, 22:2799-2809.
16. Condorelli G., Drusco A., Stassi G., Bellacosa A., Roncarati R., Iaccarino G., et al. Akt induces myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A 2002, 99:12333-12338.
17. Matsui T., Li L., Wu J.C., Cook S.A., Nagoshi T., Picard M.H., et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 2002, 277:22901-22906.
18. Everett A.D., Stoops T.D., Nairn A.C., Brautigan D. Angiotensin II regulates phosphorylation of translation elongation factor-2 in cardiac myocytes. Am J Physiol 2001, 281:H161-H167.
19. Semple D., Smith K., Bhandari S., Seymour A.M. Uremic cardiomyopathy and insulin resistance: a critical role for Akt?. J Am Soc Nephrol 2011, 22:207-215.
20. Pacher P., Bátkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58:389-462.
21. Engeli S. Dysregulation of the endocannabinoid system in obesity. J Neuroendocrinol 2008, 20:S110-S115.
22. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008, 51:1356-1367.
23. Engeli S., Böhnke J., Feldpausch M., Gorzelniak K., Janke J., Bátkai S., et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005, 54:2838-2843.
24. Silvestri C., Ligresti A., Di Marzo V. Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle. Rev Endocr Metab Disord 2011, 12:153-162.
25. Mukhopadhyay P., Bátkai S., Rajesh M., Czifra N., Harvey-White J., Hasko G., et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 2007, 50:528-536.
26. Mukhopadhyay P., Rajesh M., Bátkai S., Patel V., Kashiwaya Y., Liaudel L., et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicininduced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res 2010, 85:773-784.
27. Mukhopadhyay P., Horváth B., Rajesh M., Matsumoto S., Saito K., Bátkai S., et al. Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic Biol Med 2011, 50:179-195.
28. Rajesh M., Bátkai S., Kechrid M., Mukhopadhyay P., Lee W.S., Horváth B., et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 2012, 61:716-727.
29. Siedlecki A.M., Jin X., Muslin A.J. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 2009, 75:800-808.
30. Yang H.C., Zuo Y., Fogo A.B. Models of chronic kidney disease. Drug Discov Dis Models 2010, 7:13-19.
31. Kennedy D.J., Elkareh J., Shidyak A., Shapiro A.P., Smaili S., Mutgi K., et al. Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. Am J Physiol Renal Physiol 2008, 294:F450-F454.
32. Berti G., Fossati P., Tarenghi G., Musitelli C., Melzi d'Eril G.V. Enzymatic colorimetric method for the determination of inorganic phosphorus in serum and urine. J Clin Chem Clin Biochem 1988, 26:399-404.
33. Cheng T.H., Shih N.L., Chen S.Y., Wang D.L., Chen J.J. Reactive oxygen species modulate endothelin-I_induced c-fos gene expression in cardiomyocytes. Cardiovasc Res 1999, 41:654-662.
34. Rudolph A., Abdel-Aty H., Bohl S., Boye P., Zagrosek A., Dietz R., et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy: relation to remodeling. J Am Coll Cardiol 2009, 53:284-291.
35. Mark P.B., Johnston N., Groenning B.A., Foster J.E., Blyth K.G., Martin T.N., et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 2006, 69:1839-1845.
36. Edwards N.C., Ferro C.J., Townend J.N., Steeds R.P. Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction. Heart 2008, 94:1038-1043.
37. Tyralla K., Amann K. Cardiovascular changes in renal failure. Blood Purif 2002, 20:462-465.
38. Tyralla K., Amann K. Morphology of the heart and arteries in renal failure. Kidney Int 2003, 63:S80-S83.
39. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214:199-210.
40. Lijnen P.J., Petrov V.V., Fagard R.H. Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab 2000, 71:418-435.
41. Lijnen P., Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000, 32:865-879.
42. Pohlers D., Brenmoehl J., Loffler I., Muller C.K., Leipner C., Schultze-Mosqau S., et al. TGF-β and fibrosis in different organs-molecular pathway imprints. Biochim Biophys Acta 2009, 1792:746-756.
43. London G.M. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 2003, 16:85-94.
44. Alhaj E., Alhaj N., Rahman I., Niazi T.O., Berkowitz R., Klapholz M. Uremic cardiomyopathy: an underdiagnosed disease. Congest Heart Fail 2013, 19:E40-E45.
45. Lekawanvijit S., Adrahtas A., Kelly D.J., Kompa A.R., Wang B.H., Krum H. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?. Eur Heart J 2010, 31:1771-1779.
46. Lekawanvijit S., Kompa A.R., Manabe M., Wang B.H., Langham R.G., Nishijima F., et al. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One 2012, 7:e41281.
47. Barreto F.C., Barreto D.V., Liabeuf S., Meert N., Glorieux G., Temmar M., et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009, 4:1551-1558.
48. Shimazu S., Hirashiki A., Okumura T., Yamada T., Okamoto R., Shinoda N., et al. Association between indoxyl sulfate and cardiac dysfunction and prognosis in patients with dilated cardiomyopathy. Circ J 2013, 77:390-396.
49. Walsh K. Akt signaling and growth of the heart. Circulation 2006, 113:2032-2034.
50. DeBosch B., Sambandam N., Weinheimer C., Courtois M., Muslin A.J. Akt2 regulates cardiac metabolism and cardiomyocyte survival. J Biol Chem 2006, 281:32841-32851.
51. Lin C.Y., Hsu S.C., Lee H.S., Lin S.H., Tsai C.S., Huang S.M., et al. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure. J Vasc Surg 2013, 57:475-485.
52. Hsu Y.J., Hsu S.C., Huang S.M., Lee H.S., Lin S.H., Tsai C.S., et al. Hyperphosphatemia induces protective autophagy in endothelial cells through the inhibition of Akt/mTOR signaling. J Vasc Surg 2015, 62:210-221.
53. Hescheler J., Meyer R., Plant S., Plant S., Krautwurst D., Rosenthal W., et al. Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ Res 1991, 69:1476-1486.
54. Bugyei-Twum A., Advani A., Advani S.L., Zhang Y., Thai K., Kelly D.J., et al. High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. Cardiovasc Diabetol 2014, 13:89.
55. Zong J., Zhang D.P., Zhou H., Bian Z.Y., Deng W., Dai J., et al. Baicalein protects against cardiac hypertrophy through blocking MEK-ERK1/2 signaling. J Cell Biochem 2013, 114:1058-1065.
56. Bai Y., Cui W., Xin Y., Miao X., Barati M.T., Zhang C., et al. Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J Mol Cell Cardiol 2013, 57:82-95.
57. Singla D.K., Singla R.D., Lamm S., Glass C. TGF-β2 treatment enhances cytoprotective factors released from embryonic stem cells and inhibits apoptosis in infarcted myocardium. Am J Physiol Heart Circ Physiol 2011, 300:H1442-H1450.
58. Ghiggeri G.M., Oleggini R., Musante L., Caridi G., Gusmano R., Ravazzolo R. A DNA element in the alpha1 type III collagen promoter mediates a stimulatory response by angiotensin II. Kidney Int 2000, 58:537-548.